Changes

Jump to: navigation, search

Chronic myelomonocytic leukemia

16 bytes added, 22:31, 13 December 2019
m
no edit summary
|-
|rowspan=2|[https://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (E-esc)
|1. [[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[https://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (E-esc)
|1. [[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[https://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (E-esc)
|1. [[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[https://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (E-esc)
|1. [[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
LookupUsers, editors, emailconfirmed
24,702
edits

Navigation menu